Business
INOVIO to Report Second Quarter 2020 Financial Results on August 10, 2020
PLYMOUTH MEETING, Pa., July 27, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that second quarter 2020 financial results will be released after
About this update from Inovio Pharmaceuticals, Inc.
[{"type":"text","content":"PLYMOUTH MEETING, Pa., July 27, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that second quarter 2020 financial results will be released after the market close on August 10, 2020. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update, including the company's ongoing vaccine developments for COVID-19.\nA live and archived version of the audio presentation will be available online at http://ir.inovio.com/investors/events/default.aspx. This is a listen-only event but will include a live Q&A with analysts.\nTelephone replay will be available approximately one hour after the call at 877-344-7529 (US toll free) or 412-317-0088 (international toll) using replay access code 10146894.\nAbout INOVIO\nINOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. Specifically, INOVIO's lead candidate VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, destroyed and cleared high-risk HPV 16 and 18 in a Phase 2b clinical trial. High-risk HPV is responsible for 70% of cervical cancer, 91% of anal cancer, and 69% of vulvar cancer. Also in development are programs targeting HPV-related cancers and a rare HPV-related disease, recurrent respiratory papillomatosis (RRP); non-HPV-related cancers glioblastoma multiforme (GBM) and prostate cancer; as well as externally funded infectious disease DNA vaccine development programs in Zika, Lassa fever, Ebola, HIV, and coronaviruses associated with MERS and COVID-19 diseases. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA)/Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)/Department of Defense (DOD), GeneOne Life Science/VGXI, HIV Vaccines Trial Network, International Vaccine Institute ...